258 related articles for article (PubMed ID: 37812332)
1. Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function.
Huang X; Bindra J; Chopra I; Niewoehner J; Wan GJ
Adv Ther; 2023 Dec; 40(12):5432-5446. PubMed ID: 37812332
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of terlipressin for hepatorenal syndrome: the United States hospital perspective.
Carter JA; Huang X; Jamil K; Corman S; Ektare V; Niewoehner J
J Med Econ; 2023; 26(1):1342-1348. PubMed ID: 37729445
[TBL] [Abstract][Full Text] [Related]
3. COST EFFECTIVENESS OF USING TERLIPRESSIN TO TREAT HEPATORENAL SYNDROME.
Ferreira LM; Terrabuio DR; Ferreira CM; Mazo DFC; Haddad LBP
Arq Gastroenterol; 2022; 59(2):268-274. PubMed ID: 35830040
[TBL] [Abstract][Full Text] [Related]
4. Hepatorenal Syndrome With Acute Kidney Injury: Diagnosis and Medical Management.
Erstad BL
Ann Pharmacother; 2024 Feb; 58(2):156-164. PubMed ID: 37271967
[TBL] [Abstract][Full Text] [Related]
5. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
[TBL] [Abstract][Full Text] [Related]
6. Current Pharmacologic Therapies for Hepatorenal Syndrome-Acute Kidney Injury.
Duong N; Kakadiya P; Bajaj JS
Clin Gastroenterol Hepatol; 2023 Sep; 21(10S):S27-S34. PubMed ID: 37625864
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of terlipressin and norepinephrine for treatment of hepatorenal syndrome-acute kidney injury: A systematic review and meta-analysis.
Olson JC; Subramanian RM
PLoS One; 2024; 19(1):e0296690. PubMed ID: 38285703
[TBL] [Abstract][Full Text] [Related]
8. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.
Wong F; Pappas SC; Curry MP; Reddy KR; Rubin RA; Porayko MK; Gonzalez SA; Mumtaz K; Lim N; Simonetto DA; Sharma P; Sanyal AJ; Mayo MJ; Frederick RT; Escalante S; Jamil K;
N Engl J Med; 2021 Mar; 384(9):818-828. PubMed ID: 33657294
[TBL] [Abstract][Full Text] [Related]
9. Limited Progress in Hepatorenal Syndrome (HRS) Reversal and Survival 2002-2018: A Systematic Review and Meta-Analysis.
Thomson MJ; Taylor A; Sharma P; Lok AS; Tapper EB
Dig Dis Sci; 2020 May; 65(5):1539-1548. PubMed ID: 31571102
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis.
Facciorusso A; Chandar AK; Murad MH; Prokop LJ; Muscatiello N; Kamath PS; Singh S
Lancet Gastroenterol Hepatol; 2017 Feb; 2(2):94-102. PubMed ID: 28403995
[TBL] [Abstract][Full Text] [Related]
11. AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review.
Garcia-Tsao G; Abraldes JG; Rich NE; Wong VW
Gastroenterology; 2024 Jan; 166(1):202-210. PubMed ID: 37978969
[TBL] [Abstract][Full Text] [Related]
12. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.
Sanyal AJ; Boyer TD; Frederick RT; Wong F; Rossaro L; Araya V; Vargas HE; Reddy KR; Pappas SC; Teuber P; Escalante S; Jamil K
Aliment Pharmacol Ther; 2017 Jun; 45(11):1390-1402. PubMed ID: 28370090
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological Therapies for Hepatorenal Syndrome: A Systematic Review and Meta-Analysis.
Nanda A; Reddy R; Safraz H; Salameh H; Singal AK
J Clin Gastroenterol; 2018 Apr; 52(4):360-367. PubMed ID: 28991106
[TBL] [Abstract][Full Text] [Related]
14. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2.
Nguyen-Tat M; Jäger J; Rey JW; Nagel M; Labenz C; Wörns MA; Galle PR; Marquardt JU
United European Gastroenterol J; 2019 May; 7(4):529-537. PubMed ID: 31065370
[TBL] [Abstract][Full Text] [Related]
15. Terlipressin vs Midodrine Plus Octreotide for Hepatorenal Syndrome-Acute Kidney Injury: A Propensity Score-Matched Comparison.
Gonzalez SA; Chirikov VV; Wang WJ; Huang X; Jamil K; Simonetto DA
Clin Transl Gastroenterol; 2023 Dec; 14(12):e00627. PubMed ID: 37622521
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive Agents for Hepatorenal Syndrome: A Mixed Treatment Comparison Network Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials.
Sridharan K; Sivaramakrishnan G
J Gen Intern Med; 2018 Jan; 33(1):97-102. PubMed ID: 28924736
[TBL] [Abstract][Full Text] [Related]
17. Terlipressin in the management of adults with hepatorenal syndrome-acute kidney injury (HRS-AKI).
Kulkarni AV; Lee J; Reddy KR
Expert Rev Gastroenterol Hepatol; 2023; 17(11):1067-1079. PubMed ID: 37856367
[TBL] [Abstract][Full Text] [Related]
18. The Comparative Effectiveness of Vasoactive Treatments for Hepatorenal Syndrome: A Systematic Review and Network Meta-Analysis.
Pitre T; Kiflen M; Helmeczi W; Dionne JC; Rewa O; Bagshaw SM; Needham-Nethercott N; Alhazzani W; Zeraatkar D; Rochwerg B
Crit Care Med; 2022 Oct; 50(10):1419-1429. PubMed ID: 35777925
[TBL] [Abstract][Full Text] [Related]
19. Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome.
Piano S; Gambino C; Vettore E; Calvino V; Tonon M; Boccagni P; Gringeri E; Germani G; Burra P; Cillo U; Angeli P
Hepatology; 2021 May; 73(5):1909-1919. PubMed ID: 32870499
[TBL] [Abstract][Full Text] [Related]
20. AGA Clinical Practice Update on the Evaluation and Management of Acute Kidney Injury in Patients With Cirrhosis: Expert Review.
Flamm SL; Wong F; Ahn J; Kamath PS
Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2707-2716. PubMed ID: 36075500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
